Diamyd Medical AB (publ) (STO:DMYD.B)

Diamyd Medical AB Cash Flow Statement

Financials in millions SEK. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 28, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	-170.85	-151.85	-116.07	-103.52	60.05	9.71
Depreciation & Amortization	6.12	5.58	4.87	4.38	0.78	0.15
Asset Writedown & Restructuring Costs	5.41	5.41	-	-	-	-
Other Operating Activities	-6.97	3.77	1.69	-11.61	-145.64	0.04
Change in Accounts Receivable	3.26	-13.5	0.07	10.1	-19.57	1.13
Change in Other Net Operating Assets	6.85	21.41	-1.51	7.43	-5.1	5.85
Operating Cash Flow	-156.17	-129.18	-110.96	-93.22	-109.47	16.88
Capital Expenditures	-4.42	-8.03	-11.44	-34.65	-4.23	-1.98
Investment in Securities	6.85	-19.97	39.84	-39.91	-7.66	6.8
Other Investing Activities	-0	-0	-	6.65	144.41	-
Investing Cash Flow	2.43	-27.99	28.4	-76.72	132.53	4.82
Issuance of Common Stock	105.32	135.21	75.27	150	60	-
Other Financing Activities	13.72	7.08	11.27	-7.85	-3.28	-
Financing Cash Flow	119.04	142.28	86.54	142.16	56.72	-
Foreign Exchange Rate Adjustments	1.32	0.12	3.79	8.17	1.22	-0.04
Miscellaneous Cash Flow Adjustments	-0	-	-	-	-0	-0
Net Cash Flow	-33.4	-14.78	7.77	-19.62	81.01	21.67
Free Cash Flow	-160.6	-137.21	-122.4	-127.87	-113.69	14.9
Free Cash Flow Margin	-88240.11%	-105543.08%	-22418.32%	-28165.42%	-44937.94%	4369.80%
Free Cash Flow Per Share	-1.59	-1.45	-1.56	-1.67	-1.63	0.21
Cash Interest Paid	-	0.01	0	0.25	0.07	0.03
Levered Free Cash Flow	-103.6	-91.21	-80.42	-82.04	-82.18	-16.07
Unlevered Free Cash Flow	-103.1	-91.2	-80.42	-81.88	-81.9	-15.74
Change in Net Working Capital	-8.71	-6.67	1.45	-20.22	24.66	-6.99

Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.